Neurovance is a clinical-stage, privately held neuroscience-focused company headquartered in Cambridge, Massachusetts, developing EB-1020 SR, a non-stimulant candidate for all subtypes of adult ADHD. Interim phase 2a pilot data disclosed a statistically significant 21-point improvement on the ADHD-Rating Scale-IV after 4 weeks (p<0.0001), with final data and secondary assessments scheduled for presentation at the Society for Biological Psychiatry. The company plans to initiate a human abuse liability (HAL) study to evaluate EB-1020's abuse potential versus standard stimulants and aims to expand development to adolescents and children after demonstrating safety and efficacy in adults. Management is led by co-founder and CEO Anthony A. McKinney and other experienced neuroscience drug developers. Neurovance says EB-1020 may offer stimulant-like efficacy with lower abuse potential, addressing a large ADHD market dominated by stimulants. Neurovance was spun out of Euthymics Bioscience to advance EB-1020, a norepinephrine- and dopamine-preferring reuptake inhibitor intended for adult ADHD. The company recently completed a Phase 1 trial in healthy subjects in which EB-1020 was well tolerated and demonstrated a wide therapeutic index. EB-1020’s pharmacology combines potent NE reuptake inhibition with moderate DA inhibition and very modest 5-HT inhibition, suggesting potential symptomatic and comorbidity benefits with low abuse liability. Neurovance also holds a portfolio of research-stage reuptake inhibitors for other CNS disorders. Management includes team members who were involved in development of Strattera, positioning the company to leverage prior ADHD drug-development experience. The company is headquartered in Cambridge, Massachusetts, and has secured new financing to advance clinical development.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2014